Press release
- Fresenius Medical Care’s application of the Anemia Control Model recognized as one of only six projects chosen from over 300 submissions across all healthcare segments.
- This selection highlights Fresenius Medical Care’s commitment to improving kidney care and outcomes through innovative analytics and clinical expertise.
- Anemia Control Model, currently in use in clinics outside the United States, applies advanced AI technology to optimize anemia management in people with kidney disease and address challenges with erythropoietin and iron therapies.
Bad Homburg (November 18, 2024) Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, and its subsidiary, the Renal Research Institute (RRI), announced that their application of the Anemia Control Model (ACM) was featured at the first Centers for Medicare & Medicaid Services (CMS) artificial intelligence (AI) Demo Days in the U.S. The model leverages advanced AI to support nephrologists in optimizing anemia management for people with end-stage renal disease (ESRD).
“Being selected for CMS AI Demo Days reflects our commitment to improving the lives of people with kidney disease through practical and usable advanced, data-driven solutions,” said Frank Maddux, MD, Global Chief Medical Officer and member of management board at Fresenius Medical Care AG. “The Anemia Control Model embodies our dedication to providing nephrologists with meaningful insights that enhance care for people with advanced kidney-related anemia, improving outcomes and their quality of life.”
The ACM is designed to recommend optimal dosages of erythropoiesis-stimulating agent (ESA) and iron therapies. It helps to achieve and stabilize hemoglobin levels and iron stores in adults with ESRD. By reducing hemoglobin fluctuations, ACM supports efficient drug use while offering a decision-support tool that nephrologists can integrate into daily clinical practice.
Since 2013, ACM has been implemented in over 100 clinics within the Fresenius Medical Care network, demonstrating measurable success in achieving target hemoglobin rates, while reducing the amount of ESA needed for patients.
“We were honored to participate in CMS AI Demo Days to advance AI- driven solutions in healthcare. This recognition from CMS highlights the impact that data-driven solutions like the Anemia Control Model, combined with medical, clinical, and operational expertise, can have on kidney care,” said Len Usvyat, PhD, Senior Vice President, Head of Renal Research Institute.
CMS AI Demo Days, an initiative aimed at exploring the impact of AI in healthcare, offers healthcare organizations the opportunity to showcase AI innovations that enhance care delivery, improve patient outcomes, and promote health equity.
link